These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 14341866)
1. [APROPOS OF IN SITU IMMUNOTHERAPY OF A RHABDOMYOSARCOMA]. MEYER P Rev Immunol Ther Antimicrob; 1965; 29():1-4. PubMed ID: 14341866 [No Abstract] [Full Text] [Related]
2. [IMMUNOLOGIC ASPECTS IN THE TREATMENT OF TUMORS]. GROSSI F Clin Ter; 1964 Feb; 28():390-7. PubMed ID: 14138274 [No Abstract] [Full Text] [Related]
3. IMMUNITY AND THE TREATMENT OF CANCER. MILNER JE; EVANS CA; WEISER RS Lancet; 1964 Oct; 2(7363):816-7. PubMed ID: 14187483 [No Abstract] [Full Text] [Related]
4. EXPERIMENTS IN HOST RESISTANCE TO CANCER (IN HUMAN SUBJECTS). MURRAY G Am J Surg; 1965 Jun; 109():763-4. PubMed ID: 14283336 [No Abstract] [Full Text] [Related]
5. [At the crossroads of cancer]. Chouaib S Bull Cancer; 2013 Jun; 100(6):569-74. PubMed ID: 23735599 [TBL] [Abstract][Full Text] [Related]
6. Idiotypic network and tumor therapy. Proceedings of the First International Meeting of Immunological Approaches to Tumor Therapy by Antibodies and Tumor Cell Vaccines. Bonn, February 6, 1993. Hybridoma; 1993 Oct; 12(5):493-630. PubMed ID: 8300121 [No Abstract] [Full Text] [Related]
8. [Cancer immunology and preview to active specific cancer immunotherapy (vaccine therapy)]. Okino T Nihon Geka Hokan; 1994 Jul; 63(4):127-8. PubMed ID: 7726710 [No Abstract] [Full Text] [Related]
9. [Nonspecific active immunotherapy in the combined treatment of malignant neoplasms]. Grinevich IuA Vrach Delo; 1991 May; (5):8-11. PubMed ID: 1866926 [No Abstract] [Full Text] [Related]
10. [Cancer immunotherapy targeting WT1 product which overexpressess in various kinds of malignant neoplasms]. Oka Y; Tsuboi A; Sugiyama H Tanpakushitsu Kakusan Koso; 2003 Aug; 48(11 Suppl):1663-70. PubMed ID: 12931627 [No Abstract] [Full Text] [Related]
11. Part I: Vaccines for solid tumours. Mocellin S; Mandruzzato S; Bronte V; Lise M; Nitti D Lancet Oncol; 2004 Nov; 5(11):681-9. PubMed ID: 15522656 [TBL] [Abstract][Full Text] [Related]
12. [Molecular bases of cancer immunology]. Barrera-RodrÃguez R; Peralta-Zaragoza O; Madrid-Marina V Salud Publica Mex; 1995; 37(4):344-53. PubMed ID: 7502157 [TBL] [Abstract][Full Text] [Related]
13. Targets for active immunotherapy against pediatric solid tumors. Jacobs JF; Coulie PG; Figdor CG; Adema GJ; de Vries IJ; Hoogerbrugge PM Cancer Immunol Immunother; 2009 Jun; 58(6):831-41. PubMed ID: 19009292 [TBL] [Abstract][Full Text] [Related]
14. Active specific immunotherapy: using tumor heterogeneity to successfully fight cancer. Hanna MG; Howard J; Vermorken J Hum Vaccin Immunother; 2014; 10(11):3286-96. PubMed ID: 25483649 [No Abstract] [Full Text] [Related]
16. Efficacy of different immunotherapy approaches toward treatment of doxorubicin-resistant and doxorubicin-sensitive transplantable rhabdomyosarcoma. Belova OB; Vinnichuk UD; Shlakhovenko VA; Berezhnaya NM Exp Oncol; 2007 Dec; 29(4):272-6. PubMed ID: 18199982 [TBL] [Abstract][Full Text] [Related]
17. [Current status of immunotherapy in oncology]. Zielinski C Acta Med Austriaca; 1991; 18(1):20-4. PubMed ID: 1713730 [TBL] [Abstract][Full Text] [Related]
18. An insight into cancer immunology and immunotherapy. Thompson RB Prog Clin Pathol; 1975; 6():159-76. PubMed ID: 1105670 [No Abstract] [Full Text] [Related]